These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 35008740)

  • 1. Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma.
    Videla-Richardson GA; Morris-Hanon O; Torres NI; Esquivel MI; Vera MB; Ripari LB; Croci DO; Sevlever GE; Rabinovich GA
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma.
    Pace A; Scirocchi F; Napoletano C; Zizzari IG; D'Angelo L; Santoro A; Nuti M; Rahimi H; Rughetti A
    Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering galectin-glycan interactions for immunotherapy and immunomodulation.
    Farhadi SA; Hudalla GA
    Exp Biol Med (Maywood); 2016 May; 241(10):1074-83. PubMed ID: 27229902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Galectins in Resistance to Anticancer Therapies.
    Navarro P; Martínez-Bosch N; Blidner AG; Rabinovich GA
    Clin Cancer Res; 2020 Dec; 26(23):6086-6101. PubMed ID: 32709716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coupling pathogen recognition to innate immunity through glycan-dependent mechanisms.
    Davicino RC; Eliçabe RJ; Di Genaro MS; Rabinovich GA
    Int Immunopharmacol; 2011 Oct; 11(10):1457-63. PubMed ID: 21600310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decoding Strategies to Evade Immunoregulators Galectin-1, -3, and -9 and Their Ligands as Novel Therapeutics in Cancer Immunotherapy.
    Lau LS; Mohammed NBB; Dimitroff CJ
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissecting the signal transduction pathways triggered by galectin-glycan interactions in physiological and pathological settings.
    Laderach DJ; Compagno D; Toscano MA; Croci DO; Dergan-Dylon S; Salatino M; Rabinovich GA
    IUBMB Life; 2010 Jan; 62(1):1-13. PubMed ID: 20014236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting galectin-driven regulatory circuits in cancer and fibrosis.
    Mariño KV; Cagnoni AJ; Croci DO; Rabinovich GA
    Nat Rev Drug Discov; 2023 Apr; 22(4):295-316. PubMed ID: 36759557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The universe of galectin-binding partners and their functions in health and disease.
    Troncoso MF; Elola MT; Blidner AG; Sarrias L; Espelt MV; Rabinovich GA
    J Biol Chem; 2023 Dec; 299(12):105400. PubMed ID: 37898403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration.
    Camby I; Belot N; Rorive S; Lefranc F; Maurage CA; Lahm H; Kaltner H; Hadari Y; Ruchoux MM; Brotchi J; Zick Y; Salmon I; Gabius HJ; Kiss R
    Brain Pathol; 2001 Jan; 11(1):12-26. PubMed ID: 11145198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shaping the Immune Landscape in Cancer by Galectin-Driven Regulatory Pathways.
    Rabinovich GA; Conejo-García JR
    J Mol Biol; 2016 Aug; 428(16):3266-3281. PubMed ID: 27038510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemokines modulate glycan binding and the immunoregulatory activity of galectins.
    Sanjurjo L; Schulkens IA; Touarin P; Heusschen R; Aanhane E; Castricum KCM; De Gruijl TD; Nilsson UJ; Leffler H; Griffioen AW; Elantak L; Koenen RR; Thijssen VLJL
    Commun Biol; 2021 Dec; 4(1):1415. PubMed ID: 34931005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding the universe of cytokines and pattern recognition receptors: galectins and glycans in innate immunity.
    Cerliani JP; Stowell SR; Mascanfroni ID; Arthur CM; Cummings RD; Rabinovich GA
    J Clin Immunol; 2011 Feb; 31(1):10-21. PubMed ID: 21184154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisected, complex N-glycans and galectins in mouse mammary tumor progression and human breast cancer.
    Miwa HE; Koba WR; Fine EJ; Giricz O; Kenny PA; Stanley P
    Glycobiology; 2013 Dec; 23(12):1477-90. PubMed ID: 24037315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis.
    Méndez-Huergo SP; Blidner AG; Rabinovich GA
    Curr Opin Immunol; 2017 Apr; 45():8-15. PubMed ID: 28088061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galectins: Multitask signaling molecules linking fibroblast, endothelial and immune cell programs in the tumor microenvironment.
    Elola MT; Ferragut F; Méndez-Huergo SP; Croci DO; Bracalente C; Rabinovich GA
    Cell Immunol; 2018 Nov; 333():34-45. PubMed ID: 29602445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fine-tuning antitumor responses through the control of galectin-glycan interactions: an overview.
    Salatino M; Rabinovich GA
    Methods Mol Biol; 2011; 677():355-74. PubMed ID: 20941621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T7 peptide-decorated exosome-based nanocarrier system for delivery of Galectin-9 siRNA to stimulate macrophage repolarization in glioblastoma.
    Li C; Guan N; Liu F
    J Neurooncol; 2023 Mar; 162(1):93-108. PubMed ID: 36854924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of targeting galectins - A biomaterials-focused perspective.
    Martin-Saldaña S; Chevalier MT; Pandit A
    Biomaterials; 2022 Jul; 286():121585. PubMed ID: 35623267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycans and galectins in prostate cancer biology, angiogenesis and metastasis.
    Compagno D; Gentilini LD; Jaworski FM; Pérez IG; Contrufo G; Laderach DJ
    Glycobiology; 2014 Oct; 24(10):899-906. PubMed ID: 24939371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.